The Aluminium (Aluminum) Industry is Becoming Desperate

Ignored, tolerated, censored and cancelled

Forty years, an academic lifetime, is a long time thinking and writing about aluminium and life. You are ‘noticed’ from the publication of your first paper. You are ignored while industry ambassadors nudge and cajole line managers into acting as friendly deterrents. Your perseverance is tolerated while you build a portfolio of ‘interesting’ research. Out of the blue censorship appears through the actions of your institution. When censorship fails, you are cancelled. Collusion of academia with industry and Government in stopping scientific research was my recent fate ( https://www.aluminiumresearchgroup.com/history). A fate that in truth seems to have largely gone unnoticed by mainstream and alternative media alike.

Why has the aluminium industry chosen this time to use its influence in bringing our research to an end? I contend that it is because it is running scared of recent research published by my group. Specifically, our research on Alzheimer’s disease showing unequivocally that susceptibility to developing Alzheimer’s disease equates to a predisposition to accumulate aluminium in brain tissue. This is the alarming (for industry) conclusion of our recent research on familial Alzheimer’s disease. Aluminium is a cause of Alzheimer’s disease and while the aluminium industry may not have known this already they certainly suspected this for many years. However, perhaps the straw that broke the camel’s back was not our research on Alzheimer’s disease but our work on aluminium adjuvants used in vaccination. We showed how infiltrating cells at vaccination sites accumulate aluminium adjuvant in their cytoplasm. How these cells laden with aluminium migrate not only to lymph nodes but throughout the body and most critically into brain tissue. We identified a mechanism whereby neurotoxic amounts of aluminium could be rapidly transported and deposited in brain tissue. A mechanism whereby aluminium adjuvants could produce and encephalopathy in a vaccinated infant. The aluminium industry heard this bell tolling for aluminium adjuvants and recognised that it had to be silenced immediately. Not doing so would mean an end to the use of aluminium adjuvants in vaccines. The United Kingdom Government’s recent investment in a factory making aluminium adjuvants was certainly an incentive to bring our seminal research on aluminium adjuvants to an end and to silence that that was already published in the peer-reviewed scientific literature.

Just perhaps I am wrong and I am over-reaching myself. It has simply been a number of coincidences. The peer-reviewed evidence can be found through our website (https://www.aluminiumresearchgroup.com/). I am happy to debate the science.